Team:Uppsala University

The first half of the 20th century saw a revolution in the treatment of one of the major curses of mankind: pathogenic microorganisms. After the invention of first sulfa and later penicillin, through the fourties, fifties and sixties a large number of antibiotic drugs were quickly found. The age when many bacterial infections meant life-threatening epidemics were soon forgotten, as illnesses could now be cured by a few days with antibiotics. During the sixties and seventies, bacterial infections was largely considered to be a solved problem in the western world, and drug researchers turned to other areas.

However, evolution is a more powerful force than one can imagine, and soon the bacterias got the upper hand. In later years, it has become clear that bacterial resistance is spreading at a faster rate than anyone could imagine. Between the seventies and late nineties, no new classes of antibiotics were launched, while usage of antibiotics continued at an ever increasing rate. This created an ideal enviroment for antibiotic resistance to spread.

Today, it is estimated that, in the EU alone, 25 000 patients die yearly of multidrug resistant infections, which also increase health care costs by over 1.5 billion euro per year. Antibiotic research has been given higher priority in academic institutions over the last decade, but it is clear that drug development is and has been stalled for a long time.

But do we really have to give up classic antibiotic drugs? Team Uppsala University 2012 begs to differ. We believe that new knowledge about bacterial regulatory mechanisms can enable us to once again turn resistant bacteria sensitive to classic antibiotics. This summer, we decided to show it.